‘We just need someone who’s not crazy’: How the White House decided on Erica Schwartz for CDC director

White House Seeks Stability with Erica Schwartz as CDC Director Amid Agency Turmoil

A Search for Steady Leadership

We just need someone who s not – After twelve months marked by crisis and uncertainty, the United States Centers for Disease Control and Prevention has finally found a candidate to restore confidence in its leadership. The agency has endured a devastating shooting incident, experienced sudden shifts in its top positions, and watched its reputation as an internationally trusted public health organization fracture. When the Trump administration began searching for a replacement director, one criterion emerged above all others. A White House insider revealed to CNN that the administration’s primary concern was simple: “We just need someone who’s not crazy.” This sentiment guided a prolonged search that ultimately led to Erica Schwartz, a retired Coast Guard officer and former deputy surgeon general, receiving the nomination in April.

On Wednesday, Schwartz will stand before the Senate Health, Education, Labor and Pensions Committee for her confirmation hearing. She joins Sean Kaufman, the president’s choice for Assistant Secretary of Preparedness and Response, as they both present their cases to lawmakers. According to senior health officials and sources familiar with the selection process, Schwartz’s appointment represents an effort to stabilize an agency that has experienced nearly continuous disruption. This instability has severely damaged employee morale and eroded public trust in the administration’s health priorities.

CDC Faces Multiple Health Challenges

The urgency for competent CDC leadership has grown even more pressing in recent months. The public health organization is simultaneously managing several disease threats across different regions. International efforts include supporting containment measures for an Ebola outbreak in central Africa, while domestic operations focus on controlling a surge of parasitic diarrhea affecting numerous states. These concurrent crises demand decisive and experienced direction.

Schwartz represents a significant shift from previous candidates the administration considered, many of whom aligned closely with the “Make America Healthy Again” movement. Her extensive background includes overseeing vaccination initiatives and managing public health emergencies for the federal government. This experience contrasts sharply with Trump’s initial CDC selection, whose nomination was ultimately withdrawn after concerns emerged about his skepticism regarding vaccines—a position that would have complicated his confirmation.

Political Implications and Reactions

Schwartz’s candidacy has already received positive feedback from lawmakers, creating optimism within the White House that her confirmation could proceed rapidly. This timing aligns with the administration’s heightened attention on the upcoming midterm elections. The appointment signals a broader effort by Trump’s advisors to constrain the Health and Human Services Department, which is headed by Robert F. Kennedy Jr. and has previously operated with considerable independence in pursuing controversial reforms to vaccine policies and other fundamental health programs.

However, the decision has created divisions among different constituencies. While some mainstream public health professionals remain uncertain, the “Make America Healthy Again” supporters have expressed disappointment. Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security and spokesperson for the Infectious Diseases Society of America, offered a measured assessment:

“She’s a good and well-qualified nominee, and would be in any administration. However, the issue is not her qualifications — it’s the environment that she’s being asked to work in.”

Adalja further noted that if this appointment represents a genuine shift from recent policies, it would amount to superficial change if Kennedy remains in his position.

Meanwhile, Toby Rogers, a well-known vaccine critic, voiced strong opposition on social media platform X. He characterized Schwartz’s selection as “a slap in the face to the medical freedom base that gave Trump the presidency in 2016 and 2024.” Rogers went further, suggesting that the White House has lost sight of its midterm election strategy entirely.

A History of CDC Leadership Instability

The White House has demonstrated clear eagerness to distance the health department from negative publicity as midterm elections approach—contests that could determine Republican control of Congress and influence Trump’s legislative agenda. Vaccines have consistently proven to be a contentious issue throughout this process.

Trump initially withdrew his first choice, former congressman Dr. Dave Weldon, when his vaccine positions threatened to block congressional approval. Dr. Susan Monarez, a scientist and veteran public health official, eventually received confirmation but quickly found herself at odds with Kennedy over vaccine policies and his attempts to remove senior CDC officials. Her tenure lasted less than a month before she was dismissed.

Following Monarez’s high-profile exit last August, certain Trump officials debated whether pursuing another CDC director was worthwhile. Kennedy appointed his then-deputy secretary, Jim O’Neill, as interim leader and moved to centralize authority within the department’s political leadership in Washington. Yet both White House and HHS officials eventually grew dissatisfied with O’Neill, who spent minimal time at the CDC’s Atlanta headquarters and was viewed by political appointees as an inadequate public communicator.

The White House has not yet provided a formal response to requests for comment regarding Schwartz’s nomination. As the confirmation process moves forward, all eyes will be on whether her appointment can deliver the stability the agency desperately needs while navigating the complex political landscape surrounding public health policy.